



# Core Project R03OD032624











## Overview











High-level info about this project.

| Projects        | Name   | Award  | Publications    | Repositories   | Analytics    |
|-----------------|--|--------|-----------------|----------------|--------------|
| 1R03OD032624-01 | Using Common Fund datasets for xenobiotic localization | \$304K | 12 publications | 0 repositories | 0 properties |

## Publications

Published works associated with this project.

| ID  | Title   | Authors   | RC<br>R    | SJ<br>R | Cita<br>tion<br>s | Cit./<br>year | Journal               | Publi<br>shed | Upd<br>ated |
|---|---|---|------------|---------|-------------------|---------------|-----------------------|---------------|-------------|
| <a href="#">36116580</a> <br><a href="#">DOI</a>      | Mucoadhesive carriers for oral drug delivery.                             | Kumar, Raj<br>...1 more...<br>Nurunnabi, Md     | 10.<br>102 | 0       | 87                | 29            | J Control Release     | 2022          | -           |
| <a href="#">38065244</a> <br><a href="#">DOI</a>      | Emerging delivery approaches for targeted pulmonary fibrosis treatment.   | Diwan, Rimp<br>...2 more...<br>Nurunnabi, Md    | 9.0<br>36  | 0       | 36                | 36            | Adv Drug Deliv Rev    | 2024          | -           |
| <a href="#">38104896</a> <br><a href="#">DOI</a>  | Potentials of ionic liquids to overcome physical and biological barriers. | Beaven, Elfa<br>...7 more...<br>Nurunnabi, Md   | 5.3<br>02  | 0       | 15                | 15            | Adv Drug Deliv Rev    | 2024          | -           |
| <a href="#">36971908</a> <br><a href="#">DOI</a>  | Oral delivery of RNAi for cancer therapy.                                 | Afrin, Humayra<br>...4 more...<br>Nurunnabi, Md | 3.1<br>67  | 0       | 23                | 11.5          | Cancer Metastasis Rev | 2023          | -           |

|   |   |   |           |           |    |           |                           |      |   |
|---|---|---|-----------|-----------|----|-----------|---------------------------|------|---|
| <a href="#">36753355</a> <br><a href="#">DOI</a>      | Potential and Progress of 2D Materials in Photomedicine for Cancer Treatment.                               | Bhatt, Himanshu N<br>...5 more...<br>Nurunnabi, Md          | 2.4<br>47 | 0         | 11 | 5.5       | ACS Appl Bio Mater        | 2023 | - |
| <a href="#">37238639</a> <br><a href="#">DOI</a>      | $\beta$ -Glucan and Fatty Acid Based Mucoadhesive Carrier for Gastrointestinal Tract Specific Local and ... | Esquivel, Stephanie Vargas<br>...5 more...<br>Nurunnabi, Md | 2.3<br>38 | 1.3<br>33 | 10 | 5         | Biomolecules              | 2023 | - |
| <a href="#">37350332</a> <br><a href="#">DOI</a>      | $\beta$ -Glucan-Mediated Oral Codelivery of 5FU and Bcl2 siRNA Attenuates Stomach Cancer.                   | Afrin, Humayra<br>...6 more...<br>Nurunnabi, Md             | 1.9<br>15 | 0         | 9  | 4.5       | ACS Appl Mater Interfaces | 2023 | - |
| <a href="#">36445310</a> <br><a href="#">DOI</a>  | Myofibroblast specific targeting approaches to improve fibrosis treatment.                                  | Beaven, Elfa<br>...3 more...<br>Nurunnabi, Md               | 1.8<br>3  | 0         | 20 | 6.66<br>7 | Chem Commun (Camb)        | 2022 | - |
| <a href="#">37562554</a> <br><a href="#">DOI</a>  | A photothermal driven chemotherapy for the treatment of metastatic melanoma.                                | Bhatt, Himanshu N<br>...6 more...<br>Nurunnabi, Md          | 1.4<br>73 | 0         | 9  | 4.5       | J Control Release         | 2023 | - |

[38446352](#)   
[DOI](#) 

Liver fibrosis pathologies and potentials of  
RNA based therapeutics modalities.

Diwan,  
Rimpy  
...3 more...  
Nurunnabi,  
Md

0.4  
96

0

2

2


Drug Deliv  
Transl Res

2024

-

Publications (cumulative)

Total: 12



Notes

RCR [Relative Citation Ratio](#) 

SJR [Scimago Journal Rank](#) 

# </> Repositories

Software repositories associated with this project.

| Name | Description | Tags | Last Commit | Stars | Forks | Watchers | Commits | Issues | PRs | Issue Avg | PR Avg | Readme | Contributing | Code of Con. | License | Contrib. | Languages |
|------|-------------|------|-------------|-------|-------|----------|---------|--------|-----|-----------|--------|--------|--------------|--------------|---------|----------|-----------|
|      |             |      |             |       |       |          |         |        |     |           |        |        |              |              |         |          |           |

Built on Dec 11, 2025

Developed with support from NIH Award [U54 OD036472](#)

## Notes

- Repository For storing, tracking changes to, and collaborating on a piece of software.
- PR "Pull request", a draft change (new feature, bug fix, etc.) to a repo.
- Closed/Open Resolved/unresolved.
- Issue/PR Avg Average time issues/pull requests stay open for before being closed.

Only the main /default branch is considered for metrics like # of commits.

# of dependencies is totaled from all manifests in repo, direct and transitive, e.g. package.json + package-lock.json.

## Analytics

Website metrics associated with this project.

### Notes

Active Users      [Distinct users who visited the website](#) .

New Users      [Users who visited the website for the first time](#) .

Engaged Sessions      [Visits that had significant interaction](#) .

"Top" metrics are measured by number of engaged sessions.